BioXcel Therapeutics/$BTAI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About BioXcel Therapeutics
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Ticker
$BTAI
Sector
Primary listing
Employees
37
Headquarters
Website
BTAI Metrics
BasicAdvanced
$35M
-
-$9.09
-
-
Price and volume
Market cap
$35M
52-week high
$8.08
52-week low
$1.17
Average daily volume
893K
Financial strength
Current ratio
1.175
Quick ratio
0.957
Long term debt to equity
-103.805
Total debt to equity
-122.724
Interest coverage (TTM)
-3.04%
Profitability
EBITDA (TTM)
-50.143
Gross margin (TTM)
-28.19%
Net profit margin (TTM)
-9,070.61%
Operating margin (TTM)
-6,708.24%
Revenue per employee (TTM)
$20,000
Management effectiveness
Return on assets (TTM)
-67.31%
Return on equity (TTM)
78.16%
Valuation
Price to revenue (TTM)
16.266
Price to book
-0.37
Price to tangible book (TTM)
-0.37
Price to free cash flow (TTM)
-0.21
Free cash flow yield (TTM)
-475.92%
Free cash flow per share (TTM)
-7.757
Growth
Revenue change (TTM)
-66.96%
Earnings per share change (TTM)
-71.39%
3-year revenue growth (CAGR)
76.40%
3-year earnings per share growth (CAGR)
-51.23%
BTAI News
AllArticlesVideos
Halper Sadeh LLC Encourages BioXcel Therapeutics, Inc. Shareholders to Contact the Firm to Discuss Their Rights
Business Wire3 weeks ago
BioXcel Drug Calms Agitation At Home For Schizophrenia, Bipolar Patients
Benzinga2 months ago
BioXcel Seeks FDA Label Expansion For Schizophrenia Treatment
Benzinga3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for BioXcel Therapeutics stock?
BioXcel Therapeutics (BTAI) has a market cap of $35M as of November 16, 2025.
What is the P/E ratio for BioXcel Therapeutics stock?
The price to earnings (P/E) ratio for BioXcel Therapeutics (BTAI) stock is 0 as of November 16, 2025.
Does BioXcel Therapeutics stock pay dividends?
No, BioXcel Therapeutics (BTAI) stock does not pay dividends to its shareholders as of November 16, 2025.
When is the next BioXcel Therapeutics dividend payment date?
BioXcel Therapeutics (BTAI) stock does not pay dividends to its shareholders.
What is the beta indicator for BioXcel Therapeutics?
BioXcel Therapeutics (BTAI) does not currently have a Beta indicator.